clinical trial · NCT07490535
This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye
Pittsburgh Research Institute·phase4·not yet recruiting·n = 36
Ocular Surface DiseaseDry Eye Syndrome (DES)(Xiidra®) Lifitegrast Ophthalmic Solution 5.0%
brief summary
This is a single-center prospective open-label, clinical trial to explore proteomic expression of tear fluid biomarkers in patients with dry eye treated with Lifitegrast.
started
Mar 1, 2026
primary completion
Sep 1, 2026
completion
Nov 1, 2026
last updated
Mar 24, 2026
detailed description
Approximately 30 subjects with dry eye disease (DED) will receive Xiidra®, while 6 non DED subjects will serve as a non treatment group. The study will evaluate changes in tear fluid biomarker expression using mass spectrometry-based proteomic analysis.
official title
Single-Center, Open-Label Trial to Evaluate the Effect of Lifitegrast Ophthalmic Solution 5.0% on Tear Film Biomarkers in Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol